Table 4 Summary of the current knowledge on circulating miRNAs in the context of obesity and metabolic diseases

↓miR-126

T2D

[148]

↑miR-1, miR-21, miR-133a, and miR-208

Myocardial infarction

[150]

↑miR-122

Hepatic injury and steatosis

[151]

↑let-7e

Hypertension

[152]

↑miR-130a and miR-195

Blood pressure

[153]

miR-23a, miR-27a, miR-130, miR-195, miR-197, miR-320a, and miR-509-5p

Metabolic syndrome

[153, 154]

↑let-7g and miR-221

Female-specific in metabolic syndrome

[155]

let-7b, miR-143, and miR-221

Atherogenic as and adipogenic processes

[156]

↓miR-17-5p and miR-132

Obesity

[157]

↓miR-122, miR-324-3p, miR-375, and miR-652; ↑miR-625

Pre-gestational and gestational obesity

↑miR-140-5p, miR-142-3p, miR-222; ↓miR-532-5p, miR-125b, miR-130b, miR-221, miR-15a, miR-423-5p, and miR-520c-3p

Morbidly obese patients

[67]

↓miR-17-5p

Coronary artery disease

[205]

↑miR-33

Familial hypercholesterolemia and cardiometabolic disorders

[206]

↑miR-122

NAFLD. Insulin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipid profile

[207, 208]

↑miR-122 and miR-199a

Children obesity

[161]

↓miR-375

T1D onset

[209]